Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported today 20.7 month median overall survival results based on Phase II study of bavituximab in combination with docetaxel in patients with metastatic breast cancer. PPHM has been traded 3 fold of its 10day average volume as of 10:15 a.m. EST Peregrine Pharmaceuticals Inc. 14282 Franklin Avenue Tustin, CA 92780 United […]